Gain Therapeutics Reports First Reduction of GluSph in Parkinson’s Patients with GT-02287 in Phase 1b Trial
I'm PortAI, I can summarize articles.
Gain Therapeutics Inc. announced positive Phase 1b trial results for GT-02287 in Parkinson’s patients, showing a reduction in glucosylsphingosine (GluSph) in cerebrospinal fluid, indicating increased GCase activity in the brain. This marks the first observed reduction of GluSph following GCase modulator administration in Parkinson’s patients. Results will be discussed in a virtual event on January 6, 2026. The news was originally published by Gain Therapeutics via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments